Smooth Muscle Myosin PROTACs as a Novel Treatment for Asthma

平滑肌肌球蛋白 PROTAC 作为哮喘的新型治疗方法

基本信息

  • 批准号:
    10592797
  • 负责人:
  • 金额:
    $ 24.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-11-08 至 2024-10-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT In a 2007 editorial in NEJM, we proposed that depleting airway smooth muscle of myosin – the contractile mo- tor protein responsible for myocyte contraction – would be an effective strategy for preventing acute asthma attacks, but no drug strategy to accomplish this was available. However, a clever new class of compounds, Proteolysis Targeting Chimeras (PROTACs), has been developed that could achieve this goal. These small, bifunctional molecules catalyze proteasome degradation of a targeted protein by stimulating its ubiquitination. Each PROTAC contains one moiety that binds to the targeted protein, and is connected through a linker to a second “bait” moiety that binds an E3 ligase; when both sides are bound, the E3 ligase is brought close to the targeted protein, which it ubiquitinates and so targets for degradation. The process is catalytic because the PROTAC is released upon target degradation and is available for another cycle of target binding, E3 ligase re- cruitment, and target ubiquitination. Here, we propose to test the new idea that a PROTAC to degrade smooth muscle myosin within airway smooth muscle cells could be used as a new treatment for asthma. Smooth muscle myosin has a long half-life and slow turnover rate and so seems ideally suited for degradation by PROTACs. Depleting airway myocytes of myosin would drastically impair contraction, and PROTACs targeting smooth muscle myosin (SMM-PROTACs) should prevent acute airway constriction in eve- ryone with asthma. In this R21 proposal, we will pursue proof-of-principle experiments aimed at demonstrating SMM-PROTACs can inhibit bronchoconstriction, through the execution of four specific aims: 1) Synthesize and characterize a small series of prototype SMM-PROTACs 2) Demonstrate that SMM-PROTACs degrade smooth muscle myosin in human airway smooth muscle, but do not degrade cardiac, skeletal, or non-muscle myosins 3) Demonstrate that SMM-PROTACs inhibit constriction of airways in human lung slices 4) Demonstrate that SMM-PROTACs delivered into the airways blunt methacholine (MCh)-induced bron- choconstriction in mice Demonstration that SMM-PROTACs can inhibit bronchoconstriction by selectively stimulating degradation of smooth muscle myosin would justify their further preclinical development as a novel asthma treatment. This finding would also justify evaluation of whether SMM-PROTACs inhibit progression of other diseases in which smooth muscle contraction plays a key role.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Scott Alan Snyder其他文献

Scott Alan Snyder的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Scott Alan Snyder', 18)}}的其他基金

Utilizing Non-Functionalized Terpenes to Develop Novel Strategies and Chemoselective Transformations
利用非功能化萜烯开发新策略和化学选择性转化
  • 批准号:
    9903397
  • 财政年份:
    2019
  • 资助金额:
    $ 24.36万
  • 项目类别:
Utilizing Non-Functionalized Terpenes to Develop Novel Strategies and Chemoselective Transformations
利用非功能化萜烯开发新策略和化学选择性转化
  • 批准号:
    10397022
  • 财政年份:
    2019
  • 资助金额:
    $ 24.36万
  • 项目类别:
The Chemistry and Biology of Resveratrol-based Oligomers
白藜芦醇低聚物的化学和生物学
  • 批准号:
    7901189
  • 财政年份:
    2009
  • 资助金额:
    $ 24.36万
  • 项目类别:
The Chemistry and Biology of Resveratrol-based Oligomers
白藜芦醇低聚物的化学和生物学
  • 批准号:
    8232139
  • 财政年份:
    2009
  • 资助金额:
    $ 24.36万
  • 项目类别:
The Chemistry and Biology of Resveratrol-based Oligomers
白藜芦醇低聚物的化学和生物学
  • 批准号:
    8037629
  • 财政年份:
    2009
  • 资助金额:
    $ 24.36万
  • 项目类别:
The Chemistry and Biology of Resveratrol-based Oligomers
白藜芦醇低聚物的化学和生物学
  • 批准号:
    8440354
  • 财政年份:
    2009
  • 资助金额:
    $ 24.36万
  • 项目类别:
The Chemistry and Biology of Resveratrol-based Oligomers
白藜芦醇低聚物的化学和生物学
  • 批准号:
    7786974
  • 财政年份:
    2009
  • 资助金额:
    $ 24.36万
  • 项目类别:
The Chemistry and Biology of Resveratrol-based Oligomers
白藜芦醇低聚物的化学和生物学
  • 批准号:
    8892314
  • 财政年份:
    2009
  • 资助金额:
    $ 24.36万
  • 项目类别:
Synthesis of the myrmicarin family of natural products
杨梅苷家族天然产物的合成
  • 批准号:
    6789741
  • 财政年份:
    2004
  • 资助金额:
    $ 24.36万
  • 项目类别:
Synthesis of the myrmicarin family of natural products
杨梅苷家族天然产物的合成
  • 批准号:
    6928463
  • 财政年份:
    2004
  • 资助金额:
    $ 24.36万
  • 项目类别:

相似海外基金

Setting a new research agenda in North American pediatric acute lymphoblastic leukemia
制定北美儿童急性淋巴细胞白血病的新研究议程
  • 批准号:
    486909
  • 财政年份:
    2023
  • 资助金额:
    $ 24.36万
  • 项目类别:
    Miscellaneous Programs
Risk and Resilience in Urban Black American Acute Trauma Survivors
美国城市黑人急性创伤幸存者的风险和复原力
  • 批准号:
    10379585
  • 财政年份:
    2021
  • 资助金额:
    $ 24.36万
  • 项目类别:
Admixture analysis of acute lymphoblastic leukemia in African American children: the ADMIRAL Study
非裔美国儿童急性淋巴细胞白血病的混合分析:ADMIRAL 研究
  • 批准号:
    10307680
  • 财政年份:
    2021
  • 资助金额:
    $ 24.36万
  • 项目类别:
Risk and Resilience in Urban Black American Acute Trauma Survivors
美国城市黑人急性创伤幸存者的风险和复原力
  • 批准号:
    10489823
  • 财政年份:
    2021
  • 资助金额:
    $ 24.36万
  • 项目类别:
Risk and Resilience in Urban Black American Acute Trauma Survivors
美国城市黑人急性创伤幸存者的风险和复原力
  • 批准号:
    10687026
  • 财政年份:
    2021
  • 资助金额:
    $ 24.36万
  • 项目类别:
Admixture analysis of acute lymphoblastic leukemia in African American children: the ADMIRAL Study
非裔美国儿童急性淋巴细胞白血病的混合分析:ADMIRAL 研究
  • 批准号:
    10902170
  • 财政年份:
    2020
  • 资助金额:
    $ 24.36万
  • 项目类别:
Admixture analysis of acute lymphoblastic leukemia in African American children: the ADMIRAL Study
非裔美国儿童急性淋巴细胞白血病的混合分析:ADMIRAL 研究
  • 批准号:
    10626271
  • 财政年份:
    2020
  • 资助金额:
    $ 24.36万
  • 项目类别:
Climate Change, Heat Exposure and Acute Morbidity in a Native American Population
气候变化、高温暴露和美洲原住民的急性发病率
  • 批准号:
    8901484
  • 财政年份:
    2014
  • 资助金额:
    $ 24.36万
  • 项目类别:
Chemokine-related acute lung injury pathogenesis in African-American patients
非裔美国患者趋化因子相关的急性肺损伤发病机制
  • 批准号:
    8425913
  • 财政年份:
    2013
  • 资助金额:
    $ 24.36万
  • 项目类别:
Chemokine-related acute lung injury pathogenesis in African-American patients
非裔美国患者趋化因子相关的急性肺损伤发病机制
  • 批准号:
    9015476
  • 财政年份:
    2013
  • 资助金额:
    $ 24.36万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了